[Effect of hormonal contraception on the course of lupus nephropathy].
Influence of oral contraceptive therapy on SLE activity was evaluated in 33 female patients with lupus nephropathy. Estroprogestative preparations containing either 50 micrograms (18 cases) or 30 micrograms (11 cases) of ethinylestradiol were used in 29 courses in 28 patients. Onset or exacerbation of clinical SLE activity occurred within 3 months after starting hormonal therapy in 13 cases, an overall incidence of lupus flare-up of 44 percent, involving major renal histological lesions in 5 cases. In contrast, of 16 patients receiving pure progestogen contraceptive therapy with either discontinuous normal dosage progestogens (9 cases) or continuous low-dose norsteroids (7 cases), only one developed clinical or immunological evidence of lupus exacerbation within 3 months of hormonal therapy. We conclude that oral contraceptive therapy using estrogens, even at low dosage, is associated with a high risk of SLE exacerbation. Pure progestogens, which have proven effective and devoid of such unfavorable effects, should be preferred in these patients when hormonal contraception is needed.
D003276:Contraceptives, Oral / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000503:physiopathology*; D045167:Progesterone Congeners / Q000009:adverse effects; D013997:Time Factors
D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol
Influence de la contraception hormonale sur l'évolutivité des néphropathies lupiques.